Trending/Sean Dowdy
Mayo Clinic: Ovarian Cancer Subtypes May Predict Response to Bevacizumab
CHICAGO — Molecular sequencing could identify ovarian cancer patients who are most likely to benefit from treatment with bevacizumab (Avastin), a Mayo Clinic-led study has…
Special Topics
Sign up
Social Media Network
A network for digital healthcare communicators
Mayo Clinic Connect
An online patient support community